Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer:a randomized, open-label phase 2 study by Attard, Gerhardt & Arlt, Wiebke
 
 
University of Birmingham
Assessment of the safety of glucocorticoid
regimens in combination with abiraterone acetate
for metastatic castration-resistant prostate cancer
Attard, Gerhardt; Arlt, Wiebke
DOI:
10.1001/jamaoncol.2019.1011
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Attard, G & Arlt, W 2019, 'Assessment of the safety of glucocorticoid regimens in combination with abiraterone
acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study', JAMA
Oncology, vol. 5, no. 8, pp. 1159-1167. https://doi.org/10.1001/jamaoncol.2019.1011
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Attard G, Merseburger AS, Arlt W, et al. Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for
Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. JAMA Oncol. Published online June 27,
20195(8):1159–1167. doi:10.1001/jamaoncol.2019.1011
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Assessment of the Safety of Glucocorticoid Regimens
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IMPORTANCE Abiraterone acetate is combined with prednisone, 5 mg, twice daily for
metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg,
once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer.
Understanding the physiological effects of these and other regimens is important.
OBJECTIVE To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens.
DESIGN, SETTING, AND PARTICIPANTS Open-label, randomized clinical trial (1:1:1:1) of 164men
with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4
intervention groups between June 2013 and October 2014. Analyses were conducted from
August 2017 to June 2018.
INTERVENTIONS Abiraterone acetate, 1000mg, once daily with prednisone, 5 mg, twice daily
(n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg,
once daily (n = 42).
MAIN OUTCOMES ANDMEASURES Primary end point was nomineralocorticoid excess (grade
1 hypokalemia or grade2 hypertension) through 24 weeks (6 cycles) from treatment.
RESULTS Of 164men (median [range] age, 70 [50-90] years) randomized to receive abiraterone
acetate, 1000mg, dailywith prednisone, 5mg, twice daily, once daily, or 2.5mg twice daily, or
dexamethasone, 0.5mg, once daily, 24 (70.6%) of 34 patients (95%CI, 53.8%-83.2%), 14
(36.8%) of 38 patients (95%CI, 23.4%-52.7%), 21 (60.0%) of 35 patients (95%CI,
43.6%-74.4%), and 26 (70.3%) of 37 patients (95%CI, 54.2%-82.5%), respectively, had no
mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinarymineralocorticoid
metabolites after 8weekswere higherwith prednisone, 2.5mg, twice daily and 5mgonce daily
thanwith 5mg twice daily or dexamethasone, 0.5mg, once daily. The level of urinary
glucocorticoidmetabolites appeared higher in patientswhodid notmeet the primary end point,
regardless of glucocorticoid regimen. Total lean bodymass decreased in the prednisone groups
and total body fat increased in the prednisone, 5mg, twice daily and dexamethasone groups. In
the dexamethasone group, therewas an increase in serum insulin and homeostaticmodel
assessment of insulin resistance,while total bonemineral density decreased. In the prednisone,
5mg, twice daily, 5mgonce daily, 2.5mg twice daily, and dexamethasone groups,median
radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6months, respectively.
CONCLUSIONS AND RELEVANCE Abiraterone acetate with prednisone, 5mg, twice daily or
dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point
(95% CI excluded 50%mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg,
once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in
combination with dexamethasone appeared to be particularly active but may be associated
with adverse metabolic consequences.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01867710
JAMA Oncol. 2019;5(8):1159-1167. doi:10.1001/jamaoncol.2019.1011
Published online June 27, 2019. Last corrected on August 8, 2019.
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A birateroneacetate, 1000mg,oncedaily is approved foruse in combinationwitheitherprednisone, 5mg, twicedaily or prednisone, 5 mg, once daily based on phase
3 trials reporting improvements in overall survival for the for-
mer in patients with metastatic castration-resistant prostate
cancer (mCRPC)1,2 and for the latter innewly-diagnosed,high-
risk patients with metastatic castration-sensitive prostate
cancer.3 Prednisone, 5 mg, once daily was also used in phase
3 trials investigating the benefit of abiraterone acetate in
hormone-naive advanced prostate cancer (STAMPEDE
[NCT00268476]4 and PEACE-1 [NCT01957436]). When ad-
ministered without glucocorticoids, abiraterone acetate in-
duces a syndromeof secondarymineralocorticoid excess due
to CYP17A1 17α-hydroxylase inhibition, consequently de-
creased glucocorticoid production, and a compensatory in-
crease in adrenocorticotrophic hormone (ACTH), resulting in
a rise in steroids withmineralocorticoid properties upstream
of CYP17A1.5,6 In addition tomaximizing efficacy for treating
prostate cancer, glucocorticoids are combined with abi-
raterone acetate to prevent this syndrome; however, gluco-
corticoidexposuremayexceedphysiological requirements.Dif-
ferent glucocorticoid combination regimens have not been
formally tested with abiraterone acetate. Because prolonged
exposure to abiraterone acetate plus glucocorticoid is ex-
pected fromearlier use, there is anurgentneed to improveun-
derstandingof thephysiological effects of these treatments to
improve individualized treatment.
We aimed to evaluate administration of abiraterone ac-
etate with prednisone, 5 mg, twice daily, the lower dose of 5
mg once daily used in metastatic castration-sensitive pros-
tate cancer trials,3,4,7 and prednisone, 2.5 mg, twice daily. In
menwithprogressivemCRPC, early studies of abiraterone ac-
etate showedtumor responsewhencombinedwithdexameth-
asone, 0.5 mg, once daily,5,8 and subsequent reports de-
scribed tumor responses to abiraterone acetate after a switch
from prednisone to dexamethasone.9 Therefore, our fourth
treatment group receiveddexamethasone,0.5mg, oncedaily.
The primary end point was the absence of mineralocorticoid
excess in the first 24weeks of treatment. Additionally, we as-
sessed toxic effects related to glucocorticoid excess or andro-
gen suppression, effects on steroid biosynthesis, and antitu-
mor activity.
Methods
Patients and Study Design
In thisopen-label,parallel-arm,multicenter,phase2study, 164
asymptomaticorminimally symptomaticmenwithmCRPCre-
ceived abiraterone acetate 1000mg once daily andwere ran-
domly assigned in a 1:1:1:1 ratio, using an interactive web re-
sponse system and a computer-generated randomization
schedule, to 1 of 4 glucocorticoid regimens: prednisone, 5mg,
twice daily, prednisone, 5mg, oncedaily, prednisone, 2.5mg,
twice daily, or dexamethasone, 0.5 mg, once daily. The trial
protocol is available in Supplement 1. Study treatmentwas ad-
ministered in 28-day cycles without interruption. Partici-
pants were recruited at 22 centers in 5 countries (eTable 1 in
Supplement2). Theywere required tohavehistologicallyorcy-
tologically confirmed prostate adenocarcinoma with meta-
staticdiseasedocumentedbypositivebonescan, computed to-
mography scan, or magnetic resonance imaging and prostate
cancer progression documented by prostate-specific antigen
(PSA)according to theProstateCancerWorkingGroup210or ra-
diographically according to themodified Response Evaluation
Criteria In SolidTumors (RECIST) version 1.1.11Menwere surgi-
callyormedicallycastrated,withtestosterone levelsof less than
50ng/dL.Menwithvisceral diseasewere initially excludedun-
til a protocol amendment in November 2013 (after 61 patients
had been accrued), when they were permitted to enroll. Pa-
tientswithpriorcytotoxicchemotherapy,biologic therapy,or in-
hibitionof the androgen receptorwith abiraterone acetate plus
prednisone for the treatment ofmCRPCwere excluded.
Theplannedmaximumdurationof themain studywas39
cycles (156 weeks) after the first participating patient started
study treatment. Patients continued the main study treat-
ment until disease progression, initiation of another prostate
cancer treatment, or discontinuation of study treatment for
either safety reasons (eg, sustained toxic effects that did not
return to grade ≤1 with appropriate medical management) or
patient request. At the end of themain study,men could con-
tinue treatment ina separate extensionprotocol. Patientswith
grade3or4hypokalemiaandthosewhorequireddiuretic treat-
ment, a change in glucocorticoid dose, or palliative radio-
therapydiscontinued themain study treatment but could en-
roll in the extension protocol and restart the main study
treatment after improvement to grade≤1without diseasepro-
gression. Themain studywas completed in August 2016, and
analyses were conducted from August 2017 to June 2018.
Study visits occurred on days 1 and 15 of cycle 1, day 1 of
cycles 2 to 6, day 1 of every 3 cycles thereafter, and 4 weeks
after completing the main study. Patients reported any ad-
verse events since the prior visit, and the investigator graded
each event using the National Cancer Institute Common Ter-
minologyCriteria forAdverseEvents (NCICTCAE)version4.0.
Patients with low potassium or prior history of hypokalemia
could undergo weekly or more frequent laboratory electro-
lyte evaluation. Additional procedures are described in the
eMethods in Supplement 2.
Key Points
Question What are the physiological effects associated with
abiraterone acetate plus various glucocorticoid regimens to treat
metastatic castration-resistant prostate cancer?
Findings In this open-label, phase 2 randomized clinical trial, the
164menwith metastatic castration-resistant prostate cancer
treated with abiraterone acetate plus prednisone, 5 mg, twice or
once daily, 2.5 mg twice daily, or dexamethasone, 0.5 mg, once
daily showed nomineralocorticoid excess toxic effects (grade1
hypokalemia or grade2 hypertension) through cycle 6. Insulin
resistance and loss of total body bonemineral density at the end
of study were only significant with dexamethasone.
Meaning Lowering glucocorticoid dose combined with
abiraterone acetate requires careful monitoring for toxic effects
related tomineralocorticoid excess.
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Thestudyprotocolandamendmentswereapprovedbythe
institutional review board at each participating site, and the
study was conducted according to the provisions of the Dec-
laration of Helsinki and the International Conference onHar-
monization of Good Clinical Practice Guidelines. All patients
provided written informed consent before participating.
Outcomes
Theprimary endpoint of nomineralocorticoid excesswasde-
fined as experiencing neither of 2 mineralocorticoid excess
toxic effects, grade ≥1 hypokalemia or grade ≥2hypertension,
during the first 24 weeks of treatment (ie, 6 cycles). This end
pointwasderivedfromtreatmentemergentadverseeventdata,
defined using the Medical Dictionary for Regulatory Activi-
ties (MedDRA)12 andgradedaccording toNCICTCAEv4.0. Sec-
ondary end points were global safety profile by NCI CTCAE
v4.0; changes in plasma ACTH and urinary metabolites
(eMethods and eTable 2 in Supplement 2); incidence of exog-
enous glucocorticoid adverse effects, namely changes in fast-
ing serum insulin, homeostatic model assessment of insulin
resistance (HOMA-IR; calculated as insulin × glucose ÷ 22.5),
total lean body mass, total body fat, and bone mineral den-
sity; andclinical benefit, including antitumor activity fromse-
rum PSA values, radiographic progression-free survival, and
influence on quality of life (based on the EuroQol 5-dimen-
sion questionnaire and Functional Assessment of Cancer
Therapy-ProstateCancerquestionnaire). Total leanbodymass
andtotalbodyfatwereassessedusingbonedensityscandata.13
Toavoid artifacts in interpretationdue tobonemetastases,we
only reportbody fat changes involving thearmsandtotalbody.
An exploratory secondary objective to evaluate associations
withoutcomeandplasmaandrogen receptoraberrations14will
be reported separately.
Trial Size Calculation and Statistical Analyses
The assumption was that for a glucocorticoid regimen to be
considered of interest, 75% of patients in a treatment group
would need to meet the primary end point, based on previ-
ously reported rates ina regulatoryphase3 trial.2 Ineach treat-
ment group, an exact binomial test with a 5% 1-sided signifi-
cance level had 89% power to detect the difference between
50%and75%with a sample size of at least 30patients; a treat-
ment groupwould be rejected if 50%of patients or fewermet
the primary end point. Analyses were conducted separately
within each group, and the study was neither designed nor
powered to compare results across groups.
Changes in steroid metabolites (after 2 cycles) and exog-
enousglucocorticoid adverse effects (at cycle 12 andat theend
of the main study) were examined with the Wilcoxon signed
rank test. Values for urinary metabolites after 2 cycles were
comparedamongpatientswhomet theprimaryendpoint and
those who did not at 24 weeks using the Wilcoxon 2-sample
test. Statistical significancewasdefinedasP < .05,withnocor-
rection for multiple testing. Missing values for the end-of-
main-study visit were imputed using the last-observation-
carried-forward method; for other time points, only patients
with data were included. Patient-reported quality of life was
summarized descriptively at baseline and at cycles 6 and 18.
Radiographicprogression-free survivalwas analyzedwith the
Kaplan-Meier product-limit method. The trial was not de-
signed to compare antitumor activity between the 4 treat-
ment groups.
Results
Patient Characteristics
Of 204menassessed for study eligibility, 164 (median [range]
age, 70 [50-90] years)were randomly assigned between June
2013 and October 2014 to 1 of 4 glucocorticoid regimens (in-
tention-to-treat population) and 163 received at least 1 dose
(safety population) (Figure 1). Patient disposition details are
provided in eFigure 1 in Supplement 2. Most baseline charac-
teristicswere balanced across treatment groups, although in-
cidencesof elevatedbloodpressure at baselinewere46.3%for
prednisone, 5mg, oncedaily and ranged from26.8% to 33.4%
in theother groups.Themean time fromdiagnosis to random-
izationwas 101.4months in thedexamethasone,0.5mg, once
daily group and ranged from 59.6 to 69.2months in the other
groups (eTable 3 in Supplement 2). Between 39.0%and56.1%
ofpatients (16 to23patients) ineach treatmentgroupwere tak-
inganyantihypertensivemedicationatbaseline.Median treat-
ment exposure was 12.9 months overall (12.9, 10.6, 8.4, and
18.4 months in the prednisone, 5 mg, twice daily, once daily,
and 2.5 mg twice daily, and dexamethasone groups, respec-
tively), with amaximum follow-up time on treatment of 35.6
months.
Primary End Point
Of 163 patients who received any treatment, 19 discontinued
before week 24 without an adverse event of either grade 2 or
higher hypertension or grade 1 or higher hypokalemia; there-
fore, 144 patients were evaluable for the primary end point
(Figure 1). Of these patients, 85 (59.0%) experienced neither
grade 2 or higher hypertension nor grade 1 or higher hypoka-
lemia during the first 24 weeks of treatment andmet the pri-
mary end point. The breakdown by treatment group was 24
of 34 patients (71%; 95% CI, 54%-83%) treated with predni-
sone, 5 mg, twice daily, 14 of 38 patients (37%; 95% CI, 23%-
53%) treated with prednisone, 5 mg, once daily, 21 of 35 pa-
tients (60%; 95% CI, 44%-74%) treated with prednisone, 2.5
mg, twice daily, and 26 of 37 patients (70%; 95% CI, 54%-
83%) treatedwith dexamethasone (Table). The lower bound-
ary of the 95% CI was higher than 50% (the protocol-defined
criterion) with prednisone, 5 mg, twice daily and dexameth-
asonebut less than50%withprednisone, 5mg,oncedaily and
2.5mg twicedaily. Overall, grade 2or higher hypertensionoc-
curred in the first 24weeks in 49 (34.0%) of 144 evaluable pa-
tients, andgrade1orhigherhypokalemiaoccurred in18 (12.5%)
of 144 patients (Table), including 2 patients with grade 3 hy-
pokalemia in the prednisone, 5 mg, once daily group.
Treatment Effect on Steroid Biosynthesis
In keeping with the prednisone, 2.5mg, twice daily and 5mg
once daily groups not meeting the primary end point for ab-
sence ofmineralocorticoid excess toxic effects, plasmaACTH
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increasedsignificantlyduring treatment frombaseline tocycle
3 with abiraterone plus prednisone, 5 mg, once daily (me-
dian, 8.95 pmol/L; interquartile range [IQR], 4.39-12.63)
(P < .001) andabirateroneplusprednisone, 2.5mg, twicedaily
(median,3.97pmol/L; IQR,0.42-9.24) (P < .001).PlasmaACTH
didnot change significantlywithprednisone, 5mg, twicedaily
(median, −1.07 pmol/L; IQR, −3.08 to 0.30) (P = .16) and de-
creased significantly with dexamethasone (median, −1.82
pmol/L; IQR, −3.39 to −0.10) (P = .02) (Figure 2Aand eTable 4
in Supplement 2).
To further evaluate upregulation of steroids upstream of
CYP17A1 inhibition, urinary steroid metabolites were evalu-
ated. From baseline to cycle 3, deoxycorticosterone metabo-
lites significantly increased (all P < .001) with prednisone, 5
mg, twicedaily (absolutemedian, 11.4μg/24h; IQR,−1.9 to60.9
andmedian percentage change, 149%; IQR, −15% to 324%); 5
mgoncedaily (absolutemedian,75.9μg/24h; IQR,46.7 to176.2
andmedianpercentage change, 862%; IQR, 351%-1491%); and
2.5mg twice daily (absolutemedian, 100.5 μg/24 h; IQR, 36.9
to 158.6 and median percentage change, 716%; IQR, 402%-
1391%) but not with dexamethasone (Figure 2B and eTable 4
in Supplement 2). Corticosteronemetabolites significantly in-
creased (eachP < .001)withprednisone, 5mg, oncedaily (ab-
solute median, 4452.6 μg/24 h; IQR, 2610.2-6573.0 and me-
dian percentage change, 984% IQR, 622%-1851%) and
prednisone,2.5mg, twicedaily (absolutemedian,4913.5μg/24
h; IQR, 1650.6 to7787.9andmedianpercentagechange, 1016%;
IQR, 471%-1846%) (eFigure 2A and eTable 4 in Supple-
ment 2). At first assessment, at cycle 3, median suppression
of urinary excretionofmajor androgenmetabolites androste-
Figure 1. Trial Consort Diagram
204 Patients assessed for eligibility
41 Assigned to treatment
(intention-to-treat
analyses)
41 Assigned to treatment
(intention-to-treat
analyses)
40 Assigned to treatment
(intention-to-treat
analyses)
42 Assigned to treatment
(intention-to-treat
analyses)
Prednisone, 5 mg,
twice daily
Prednisone, 5 mg,
once daily
Prednisone, 2.5 mg,
twice daily
Dexamethasone, 0.5 mg,
once daily
40 Excluded
39 Did not meet inclusion criteria
1 Declined to participate
41 Received assigned
treatment
(safety analyses)
41 Received assigned
treatment
(safety analyses)
39 Received assigned
treatment
(safety analyses)
42 Received assigned
treatment
(safety analyses)
34 Evaluable for primary
end pointa
38 Evaluable for primary
end pointa
35 Evaluable for primary
end pointa
37 Evaluable for primary
end pointa
7 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
3 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
4 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
5 Discontinued
by week 24,
not due to 
hypertension or
hypokalemia
164 Randomly assigned
a Evaluable patients completed the
24 weeks of treatment or
discontinued treatment early and
experienced either hypertension
(National Cancer Institute Common
Terminology Criteria for Adverse
Events grade2) or hypokalemia.
Reasons for treatment
discontinuation are provided in the
eFigure in the Supplement.
Table. Primary End Point: Mineralocorticoid Excess Adverse Events During the First 24Weeks
Variable
Treatment Groupa
Prednisone, 5 mg,
Twice Daily
(n = 34)b
Prednisone, 5 mg,
Once Daily
(n = 38)b
Prednisone, 2.5
mg, Twice Daily
(n = 35)b
Dexamethasone,
0.5 mg, Once Daily
(n = 37)b
Met the primary end pointc
No. (%) 24 (71) 14 (37) 21 (60) 26 (70)
95% CI (54-83) (23-53) (44-74) (54-83)
Investigator reported an adverse event
Grade ≥2 hypertension and grade
≥1 hypokalemia, No. (%)
2 (6) 1 (3) 3 (9) 2 (5)
Grade ≥2 hypertension alone, No.
(%)
7 (21) 18 (47) 10 (29) 6 (16)
Grade ≥1 hypokalemia alone, No.
(%)
1 (3) 5 (13) 1 (3) 3 (8)
a Patients in all treatment groups
received abiraterone acetate.
b Patients completed the 24 weeks of
treatment (6 cycles) or
discontinued treatment early and
experienced either hypertension
(National Cancer Institute Common
Terminology Criteria for Adverse
Events grade2) or hypokalemia.
c Investigator reported neither
hypertension (National Cancer
Institute Common Terminology
Criteria for Adverse Events grade
2) nor hypokalemia during the
first 24 weeks (6 cycles).
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rone (eFigure 2B in Supplement 2) and dehydroepiandros-
terone (eFigure 2C in Supplement 2) was greater than 90%
(eTable 4 in Supplement 2). Androgen precursor metabolites
were also significantly suppressed (both P < .001) with pred-
nisone, 5 mg, twice daily (absolute median, −330.8 μg/24 h;
IQR, −555.5 to −165.8 and median percentage change, −81%;
IQR, −89% to −63%) and dexamethasone (absolute median,
−262.1 μg/24 h; IQR, −369.0 to −89.5 andmedian percentage
change, −88%; IQR, −93% to −56%). However, androgen pre-
cursormetaboliteswerenotsignificantlysuppressedwithpred-
nisone, 5 mg, once daily or 2.5 mg twice daily (Figure 2C and
eTable 4 in Supplement 2).
In exploratory analyses, 24-hour urinary excretion of cor-
ticosteronemetabolites (eFigure 3A in Supplement 2), cortisol
(Figure 2D), and cortisone (eFigure 3B in Supplement 2) were
significantlyhigher inpatients in any treatmentgroupwhoex-
perienced grade 2 or higher hypertension or grade 1 or higher
hypokalemia in the first 24weeks of the study comparedwith
patientswithouteitheradverseevent(eTable5inSupplement2).
Adverse Events
Over the main study, grade 3 adverse events of hypertension
were reported in 7% (n = 3), 22% (n = 9), 13% (n = 5), and 7%
(n = 3) of patients in the prednisone, 5 mg, twice daily, pred-
nisone, 5mg, once daily, prednisone, 2.5mg, twice daily, and
dexamethasonegroups, respectively.Grade3hypokalemiawas
reported in 7.3% (n = 3) of patients in the prednisone, 5 mg,
once daily group and in no other patients; all other events of
hypokalemia were grade 1 or grade 2 (eTable 6 in Supple-
ment 2). Neither grade 4 hypokalemia nor grade 4 hyperten-
sion were reported, and no patient discontinued study treat-
ment for persistent hypertension. One patient in the
Figure 2. Changes FromBaseline to Cycle 3 in the 4 Treatment Arms and the AssociationWith Toxic Effects
of Sum ofMetabolites of Cortisol at Cycle 3
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prednisone, 5mg, once daily groupwith an unrelated gastro-
intestinal illness had a prolongedhospitalization for a serious
adverse event of hypokalemia. No patient had a serious ad-
verse event of hypertension. Cumulative incidences of hyper-
tension and hypokalemia over time are shown in eFigure 4 in
Supplement 2. Other adverse events of interest such as pe-
ripheral edema, cardiac effects, and liver function are sum-
marized in eTable 7 in Supplement 2.
Long-termMetabolic andMusculoskeletal Effects
Insulin resistancewas evaluatedby recording changes in fast-
ing serum insulin or HOMA-IR. The mean change from base-
line for fastingseruminsulin inallpatientswas9.2pmol/L (95%
CI, −14.5 to 33.0) at cycle 12 and 17.7 pmol/L (95%CI, 1.0-34.3)
at the end of the main study. Significant increases in fasting
serum insulin andHOMA-IRwere observed in the dexameth-
asone group only, both at cycle 12 (fasting serum insulin, 53.7
pmol/L; 95% CI, 16.6-90.8; P < .001 and HOMA-IR, 2.15; 95%
CI,0.24-4.07;P = .004) (Figure3A,B)andat theendof themain
study (fasting serum insulin, 47.5 pmol/L; 95% CI, 18.8-76.2;
P = .002andHOMA-IR, 1.99; 95%CI, 0.59-3.38;P = .01) (eFig-
ure 5 in Supplement 2). No patient required insulin. Two pa-
tients started medications for non–insulin-dependent diabe-
tes (both were in the dexamethasone group).
Body composition showed a significant decrease in total
lean bodymass from baseline to cycle 12 in the prednisone, 5
mg, twice daily (−5.8%; 95% CI, −8.6% to −3.0%) (P < .001),
prednisone, 5mg, oncedaily (−2.5%; 95%CI, −4.9% to -0.0%)
(P = .02), and prednisone, 2.5mg, twice daily groups (−5.6%;
95%CI, −8.5% to−2.6%;P < .001) (Figure 3C) and in all groups
at the end of the main study (eFigure 5 in Supplement 2). In
keepingwithhigher glucocorticoid exposure, a significant in-
crease in total body fat in theprednisone, 5mg, twicedaily and
dexamethasone groups was observedwhen comparing base-
line to cycle 12 (12.3%; P = .001 and 19.2%; P < .001, respec-
tively) (Figure 3D) or to the end of the main study (eFigure 5
Figure 3. Changes FromBaseline to Cycle 12 by Treatment Group
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in Supplement 2) but was not observedwith the lower gluco-
corticoid regimens. A small but significant decrease in total
bodybonemineraldensity frombaseline to theendof themain
studywas seen in the dexamethasone group (−2.0%; 95%CI,
−3.4% to −0.6%); no other change in the bone mineral den-
sity of the total body or the arms was observed at cycle 12 or
at the end of the main study (eTable 8 in Supplement 2).
Clinical Benefit
Among the 164 randomized patients evaluated, a PSA de-
crease of greater than or equal to 50%was observed in 26 pa-
tients (63.4%; 95% CI, 48.1%-76.4%) treated with predni-
sone, 5 mg, twice daily, 32 (78.0%; 95% CI, 63.3%-88.0%)
treatedwithprednisone, 5mg, oncedaily, 24 (60.0%; 95%CI,
44.6%-73.7%) treatedwithprednisone,2.5mg, twicedaily, and
37 (88.1%; 95% CI, 75.0%-94.8%) treated with dexametha-
sone (Figure 4 and eTable 9 in Supplement 2). Median radio-
graphic progression-free survival was 18.5 months (95% CI,
10.0-26.7)withprednisone,5mg, twicedaily, 15.3months (95%
CI, 8.4-29.5) with prednisone, 5 mg, once daily, 12.8 months
(95% CI, 7.4-20.9) with prednisone, 2.5 mg, twice daily, and
26.6 months (95% CI, 20.9-not evaluable) with dexametha-
sone (eFigure 6A in Supplement 2). Patient-reported quality
of life in this population, which was asymptomatic or mini-
mallysymptomaticpretreatment, remainedstable inallgroups,
supporting no detectable reduction secondary to treatment
(eFigure 6B in Supplement 2).
Discussion
Abirateroneacetateplusprednisone isbeingusedearlier in the
treatment paradigm for prostate cancer and because patients
benefit for a longer period, treatment exposure is increased.
We therefore designed a randomized clinical trial to support
physician decision making in selecting a glucocorticoid regi-
Figure 4. Prostate-Specific Antigen Declines by Treatment Group
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men that balances controllingmanifestations of endogenous
mineralocorticoid excess with the adverse consequences of
nonphysiological exposure to exogenous glucocorticoids.
Manifestations of endogenous mineralocorticoid excess of-
ten present within 24 weeks of treatment, whereas the ad-
verse consequences associated with exogenous glucocorti-
coids are usually associated with cumulative exposure.
Prednisone, 5 mg, twice daily and dexamethasone, 0.5 mg,
oncedailymet theprespecified threshold for theprimary end
point (the95%CIexcluded50%mineralocorticoidexcess), but
prednisone, 5 mg, once daily and 2.5 mg twice daily did not
meet the threshold.
We selected hypertension and hypokalemia as indicators
of clinically relevant mineralocorticoid excess because other
clinical features, including lower limbedemaandgeneral fluid
overload, are less feasible to standardize in amulticenter trial.
To support our clinical end point, we confirmed a significant
rise in plasma ACTH and a subsequent rise in mineralocorti-
coidproductionwith the lowerprednisonedoses.Wehypoth-
esize thatmonitoringofurinaryglucocorticoidmetabolite lev-
els could identify patients at risk of mineralocorticoid excess
and allow tailoring of the glucocorticoid dose.
A strength of the trial was monitoring for long-term ad-
verseeffectsof glucocorticoidexcess.Total leanbodymassde-
creased significantly in all 3 prednisonegroups and total body
fat increased significantly in theprednisone, 5mg, twicedaily
anddexamethasonegroups. Significant increases in insulin re-
sistance and decreases in total bonemineral densitywere ob-
served onlywith dexamethasone. Androgen precursorswere
significantly suppressed with dexamethasone, 0.5 mg, once
daily and prednisone, 5mg, twice daily. The antitumor activ-
ity associatedwith abiraterone acetate plus glucocorticoids in
thepresent studywas similar to previous reports1,2 in this dis-
ease setting; dexamethasone appearedparticularly active but
may be associated with adverse metabolic consequences.
Limitations
A limitation of the trial is that the size calculation was based
ontheprimaryendpoint related to thesafetyof individual regi-
mens; therefore, the number of patients accrued does not al-
lowfordirect comparisonsamong the4 treatmentgroups. Sec-
ond, althoughpatientswere randomly assigned to treatment,
differences at baseline could contribute to differences in out-
comes. Third, testing for physiological effects and their asso-
ciation with clinical manifestation of mineralocorticoid ex-
cess were exploratory analyses, and we did not correct for
multiple testing. Overall, the observations of our phase 2 trial
require further validation.
Conclusions
This trial provides results consistentwith the approveduse of
abiraterone acetatewith prednisone, 5mg, twice daily for the
treatment ofmCRPC. Long-termadversemetabolic andmus-
culoskeletal changes are small anddonot appear tohaveadet-
rimental effectonpatient-reportedqualityof life.Differentglu-
cocorticoid regimens make distinct compromises on control
ofmineralocorticoidexcess, changes inbodycomposition, and
development of insulin resistance. With careful monitoring,
the risk of hypokalemia with lower glucocorticoid doses can
be mitigated, as demonstrated in the LATITUDE and STAM-
PEDE trials where no major safety concerns were raised.3,4 A
lowerdose of prednisone appears to reduce long-term risks of
insulin resistance, increased body fat, and loss of bone min-
eral density.
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Invited Commentary
Ideal Glucocorticoid RegimenWith Abiraterone Acetate
Options and Challenges
Umang Swami, MD; Sumanta K. Pal, MD; Neeraj Agarwal, MD
Abiraterone acetate, 1000 mg, once daily is approved for the
treatment of metastatic castration-resistant prostate cancer
(mCRPC) and high-risk metastatic castration-sensitive pros-
tatecancer(mCSPC)incombinationwithprednisone,5mg,orally
twice daily or once daily,
respectively.1 However, the
idealdoseofprednisonecom-
binedwithabirateroneacetateisnotknown.Inthis issueofJAMA
Oncology, Attard and colleagues2 report on the safety results of
aphase2studyofabirateroneacetate incombinationwith4dif-
ferent glucocorticoid regimens in themCRPC setting.
In thismulticenter study,2 164patientswithmCRPCwere
randomized to receive abiraterone acetate with prednisone,
5mg, twicedaily (n = 41), 5mgoncedaily (n = 41), 2.5mgtwice
daily (n = 40) or dexamethasone, 0.5mg, once daily (n = 42).
The primary end point for this studywas defined as no grade
1orhigherhypokalemiaor grade2orhigherhypertensiondur-
ing the first 24 weeks (6 cycles) of treatment and no group
crossing the lower 95% CI boundary of 50% mineralocorti-
coid excess. Overall, 24 (71%) of 34 patients (95% CI, 54%-
83%) treated with prednisone, 5 mg, twice daily, 14 (37%) of
38 (95% CI, 23%-53%) treated with prednisone, 5 mg, once
daily, 21 (60%) of 35 (95% CI, 44%-74%) treated with 2.5 mg
twicedaily, and26 (70%)of 37 (95%CI, 54%-83%) treatedwith
dexamethasone,0.5mg,oncedailymet theprimaryendpoint.
Theprespecified threshold for theprimaryendpointwas there-
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